TY - JOUR
T1 - RAPID–LC
T2 - rapid evidence-to-practice uptake of large core thrombectomy across a stroke consortium
AU - Mir, Osman
AU - Al Matairi, Alzahra’a
AU - Nguyen, Dan
AU - Sarraj, Amrou
AU - Dmytriw, Adam A.
AU - Siddiqui, Adnan H.
AU - Grandhi, Ramesh
AU - Dolia, Jaydevsinh N.
AU - Haussen, Diogo C.
AU - Al-Bayati, Alhamza R.
AU - Nogueira, Raul G.
AU - Eby, Brendan
AU - Alaraj, Ali
AU - Bushnaq, Saif
AU - Burkhardt, Jan Karl
AU - Srinivasan, Visish
AU - Masoud, Hesham
AU - Sangha, Navdeep
AU - Lee, Angus
AU - Ashouri, Yazan
AU - Farooqui, Imran
AU - Alderazi, Yazan J.
AU - Ogola, Gerald
AU - Akkihal, Kartik
AU - Beltagy, Abdelrahaman
AU - Duncan, Kelsey R.
AU - Li, Yan Lin
AU - Przepiorka, Lukasz
AU - Shoraka, Omid
AU - Yelam, Theja
AU - Doheim, Mohamed F.
AU - Heitsch, Laura
AU - Abou-Mrad, Tatiana
AU - Suppakitjanusant, Pichatorn
AU - Scott, Kyle
AU - Begum, Momotaz
AU - AlMajali, Mohammand
AU - Al-Shaibi, Faisal
AU - Zhang, Zheqing
AU - Pekyi-Boateng, Prince
AU - Siddu, Mithilesh
AU - Khasawneh, Mohammad
AU - Adegoke, Michael
AU - Vijil, Myriam
AU - Akouri, Habib
AU - Ali, Zuhair
AU - Zaidat, Osama
AU - Ezzeldin, Mohamad
N1 - Publisher Copyright:
© Springer-Verlag GmbH Germany, part of Springer Nature 2026.
PY - 2026/6
Y1 - 2026/6
N2 - Background: Recent landmark trials, including SELECT2, ANGEL-ASPECT, and RESCUE-Japan LIMIT, demonstrated the benefit of endovascular thrombectomy (EVT) in patients with large ischemic cores, primarily among those with ASPECTS 3–5, with limited representation of ASPECTS 0–2. However, real-world adoption across the full spectrum of low ASPECTS remains uncertain. Methods: We conducted a retrospective, multicenter, before–and–after cohort study comparing the pre-publication (July–December 2021, n = 150) and post-publication (January–June 2024, n = 195) periods. Adults presenting within 24 h of large vessel occlusion stroke with large cores (ASPECTS ≤ 5 or CT core > 70 mL) were included. The primary outcome was EVT utilization (receipt of thrombectomy). Secondary outcomes were 30- and 90-day modified Rankin Scale (mRS) and mortality. Safety outcomes included symptomatic intracranial hemorrhage and procedural complications. Multivariable logistic regression identified independent predictors of receiving EVT, adjusting for clinical and imaging variables. Results: A total of 345 patients were included (median age 70 years, 52% male). EVT utilization increased from 42% (63/150) in 2021 to 60.5% (118/195) in 2024. In multivariable analysis, the year 2024 was the strongest independent predictor of receiving EVT (adjusted OR 3.11; p < 0.001). ASPECTS score was the dominant imaging predictor of receiving EVT (adjusted OR 7.11 for ASPECTS 3–5 vs 0–2). EVT use in patients with ASPECTS 0–2 increased from 4.3 to 32.5%. Among treated cohorts, mortality increased non-significantly from 27 to 33.9% (p = 0.340). Functional outcomes at 30 and 90 days did not differ significantly between cohorts. Conclusion: Publication of large core thrombectomy trials was associated with substantial increases in endovascular thrombectomy use in large-core stroke, including among patients with very low ASPECTS, with a non-significant increase in symptomatic intracranial hemorrhage and a decline in favorable functional outcomes. Clinician adherence to baseline severity considerations (ASPECTS, age, and premorbid function) appears appropriate. These findings demonstrate the safe and rapid translation of evidence into practice and highlight the importance of standardized implementation strategies to optimize patient outcomes.
AB - Background: Recent landmark trials, including SELECT2, ANGEL-ASPECT, and RESCUE-Japan LIMIT, demonstrated the benefit of endovascular thrombectomy (EVT) in patients with large ischemic cores, primarily among those with ASPECTS 3–5, with limited representation of ASPECTS 0–2. However, real-world adoption across the full spectrum of low ASPECTS remains uncertain. Methods: We conducted a retrospective, multicenter, before–and–after cohort study comparing the pre-publication (July–December 2021, n = 150) and post-publication (January–June 2024, n = 195) periods. Adults presenting within 24 h of large vessel occlusion stroke with large cores (ASPECTS ≤ 5 or CT core > 70 mL) were included. The primary outcome was EVT utilization (receipt of thrombectomy). Secondary outcomes were 30- and 90-day modified Rankin Scale (mRS) and mortality. Safety outcomes included symptomatic intracranial hemorrhage and procedural complications. Multivariable logistic regression identified independent predictors of receiving EVT, adjusting for clinical and imaging variables. Results: A total of 345 patients were included (median age 70 years, 52% male). EVT utilization increased from 42% (63/150) in 2021 to 60.5% (118/195) in 2024. In multivariable analysis, the year 2024 was the strongest independent predictor of receiving EVT (adjusted OR 3.11; p < 0.001). ASPECTS score was the dominant imaging predictor of receiving EVT (adjusted OR 7.11 for ASPECTS 3–5 vs 0–2). EVT use in patients with ASPECTS 0–2 increased from 4.3 to 32.5%. Among treated cohorts, mortality increased non-significantly from 27 to 33.9% (p = 0.340). Functional outcomes at 30 and 90 days did not differ significantly between cohorts. Conclusion: Publication of large core thrombectomy trials was associated with substantial increases in endovascular thrombectomy use in large-core stroke, including among patients with very low ASPECTS, with a non-significant increase in symptomatic intracranial hemorrhage and a decline in favorable functional outcomes. Clinician adherence to baseline severity considerations (ASPECTS, age, and premorbid function) appears appropriate. These findings demonstrate the safe and rapid translation of evidence into practice and highlight the importance of standardized implementation strategies to optimize patient outcomes.
KW - ASPECTS score
KW - Endovascular thrombectomy
KW - Implementation
KW - Large core infarction
KW - Outcomes
KW - Practice patterns
UR - https://www.scopus.com/pages/publications/105040415839
U2 - 10.1007/s00415-026-13866-2
DO - 10.1007/s00415-026-13866-2
M3 - Article
C2 - 42189238
AN - SCOPUS:105040415839
SN - 0340-5354
VL - 273
JO - Journal of Neurology
JF - Journal of Neurology
IS - 6
M1 - 343
ER -